Global Computational Biology Market was valued at US$ 2.5 Bn in 2017 and is expected to reach US$10.7Bn by 2026, at a CAGR of 19.93% during a forecast period.
The global computational biology market has witnessed significant growth in recent years because of its assistance in the field of biotechnology and medicine. Combing biology and computers, computational biology helps in drug breakthroughs and consequent development during the several stages of clinical trials. The wide use of computational biology in biotechnology and pharmaceuticals driving the market.
Lack of innovative drugs and increasing drug failures in later stages of development had taken its toll on the pharmaceutical industry, amounting to huge financial losses. However, adopting computational biology above a period of time has led to not just minimized clinical stage expenditure but also decreased the frequency of drug failures. This has mainly driven the computational biology market. Additionally, enhanced government funding and industrial support, as well as improved computational tools have driven the growth of the industry. The use of computational biology in modelling and simulation of paediatrics drug development is expected to open various doors for future expansion.
DOWNLOAD FREE SAMPLE REPORT: https://www.maximizemarketresearch.com/market-report/global-computational-biology-market/30234/#requestforsample
Cellular and biological simulation segment is expected to continue leading with over 34.0% market share by 2026. Computational cell modelling and biological simulation aid decipher the biological and physiological functions of cells. Increased unmet medical desires and burgeoning demand for personalized medicine are expected to shape the future growth of the application segment.
Commercial led the end use segment in 2017, attributed to the rise in the bioinformatics research, drug designing, and usage in personalized medicine. Such as, in August 2018, the European Union and India’s Department of Biotechnology (DBT) announced the fund of US$ 17.2 Mn towards research and innovation for the development of next-generation influenza virus to protect individuals worldwide.
North America is expected to contribute to the largest market share in the computational biology market in the coming years, because of increasing investments made in R&D activities for the discovery as well as the development of novel drugs. Also, the Asia Pacific is anticipated to witness steady growth during the forecast period, owing to increasing clinical trials in the region.
In Feb 2019, StemoniX Inc., the USA based provider of product and services for drug discovery and development, received funding of US$ 14.40 Mn from a group of investors. Brightstone Venture Capital was the major financer and was later combined by Crescent Ridge Partners, Alumni Ventures Group, and Mayo Clinic.
The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding Global Computational Biology Marketdynamics, structure by identifying and analyzing the market segments and project the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence. The report also provides PEST analysis, PORTER’s analysis, SWOT analysis to address the question of shareholders to prioritizing the efforts and investment in the near future to the emerging segment in the Global Computational Biology Market.
Scope of the Global Computational Biology Market
Global Computational Biology Market, by Application
o Computational Genomics
Software & Services
o Computational Proteomics
o Others (Transcriptomics/ Metabolomics)
• Drug Discovery & Disease Modelling
o Target Identification
o Target Validation
o Lead Discovery
o Lead Optimization
• Preclinical Drug Development
• Clinical Trials
o Phase I
o Phase II
o Phase III
• Human Body Simulation Software
• Asia Pacific
• Middle East and Africa
• South America
• Chemical Computing Group ULC
• Compugen Ltd
• Rosa & Co. LLC
• Genedata AG
• Insilico Biotechnology AG
• Leadscope Inc.
• Nimbus Discovery LLC
• Strand Life Sciences
• Simulation Plus Inc.
Maximize Consulting, are a strong unified team of industry specialists and analysts across sectors to ensure entire Industry ecosystem is taken in perspective, factoring all recent development, latest trends and futuristic – the technological impact of uniquely specific industries. In line with the agreed scope and objective of the study, our approach is uniquely custom detailed.